Use and cost of psychotropic drugs among recipients with autism in a state Medicaid fee-for-service programme
Article first published online: 4 APR 2012
© 2012 The Authors. Journal of Intellectual Disability Research © 2012 Blackwell Publishing Ltd
Journal of Intellectual Disability Research
Special Issue: Mental Health and Intellectual Disability: XXIXII
Volume 57, Issue 2, pages 161–171, February 2013
How to Cite
Khanna, R., Jariwala, K. and West-Strum, D. (2013), Use and cost of psychotropic drugs among recipients with autism in a state Medicaid fee-for-service programme. Journal of Intellectual Disability Research, 57: 161–171. doi: 10.1111/j.1365-2788.2012.01563.x
- Issue published online: 4 JAN 2013
- Article first published online: 4 APR 2012
- Accepted 2 March 2012
- psychotropic drugs
Background There has been a significant increase in the prevalence of autism in the USA in the past few decades. The purpose of this study was to provide recent estimates of psychotropic drug use and costs among individuals with autism enrolled in Medicaid programme.
Method A cross-sectional analysis of 2007 Mississippi (MS) Medicaid fee-for-service (FFS) programme administrative-claims data was performed. Study sample included recipients (<65 years) who had a medical services claim with a diagnosis of autism in 2007. Psychotropic drug patterns of use and costs were studied. Factors predicting the use of psychotropic drugs were identified using logistic regression analyses. Average number and cost of psychotropic drug claims per recipient were reported. Costs were reported from the perspective of MS Medicaid.
Results In 2007, there were 1330 recipients with a diagnosis of autism in MS Medicaid FFS programme. Among these recipients, 66.32% had a claim for psychotropic drug during the year. Roughly 39% of recipients with autism had a claim for antipsychotics, 31.58% for stimulants, 19.55% for antidepressants, 19.40% for other psychotropics and 14.81% for anxiolytics/hypnotics/sedatives. Results from regression analyses highlighted variation in psychotropic drug use by demographic and co-morbid factors. There were a total of 12 618 claims for psychotropic drugs filled by recipients with autism in 2007, at an average of 14 (±12) claims per recipient. The total cost of these claims paid for by MS Medicaid FFS programme was ∼$2 million. Antipsychotics accounted for more than half (∼58%) of the total costs, and had the highest average cost per claim ($291 ± 205).
Conclusions The results of this study indicate a high use of psychotropic drugs among individuals with autism enrolled in a state Medicaid programme. There is an urgent need to study the risk–benefit profile of these drugs in this growing population. Psychotropic drug use was found to vary by demographic and co-morbid factors. Among the different classes of psychotropic drugs, antipsychotics were the most commonly used and had the highest cost per claim.